1. A Mechanistic Model of Drug‐Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial. (5th February 2014) Authors: Howell, BA; Siler, SQ; Shoda, LKM; Yang, Y; Woodhead, JL; Watkins, PB Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 3:Number 2(2014) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Issue 4 (22nd February 2016) Authors: Fannin, RD; Gerrish, K; Sieber, SO; Bushel, PR; Watkins, PB; Paules, RS Journal: Clinical pharmacology & therapeutics Issue: Volume 99:Issue 4(2016:Apr.) Page Start: 432 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management. Issue 4 (11th January 2017) Authors: Mosedale, M; Watkins, PB Journal: Clinical pharmacology & therapeutics Issue: Volume 101:Issue 4(2017) Page Start: 469 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury. (13th January 2016) Authors: Longo, DM; Yang, Y; Watkins, PB; Howell, BA; Siler, SQ Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 5:Number 1(2016:Jan.) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI. (9th July 2014) Authors: Woodhead, JL; Yang, K; Brouwer, KLR; Siler, SQ; Stahl, SH; Ambroso, JL; Baker, D; Watkins, PB; Howell, BA Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 3:Number 7(2014) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials. Issue 6 (27th May 2017) Authors: Longo, DM; Generaux, GT; Howell, BA; Siler, SQ; Antoine, DJ; Button, D; Caggiano, A; Eisen, A; Iaci, J; Stanulis, R; Parry, T; Mosedale, M; Watkins, PB Journal: Clinical pharmacology & therapeutics Issue: Volume 102:Issue 6(2017) Page Start: 961 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters. Issue 4 (17th February 2017) Authors: Yang, K; Battista, C; Woodhead, JL; Stahl, SH; Mettetal, JT; Watkins, PB; Siler, SQ; Howell, BA Journal: Clinical pharmacology & therapeutics Issue: Volume 101:Issue 4(2017) Page Start: 501 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗